Top

Published in:

Open Access 01-12-2020 | Correction

Correction to: Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts

Authors: Serena Colafrancesco, Maria Manara, Alessandra Bortoluzzi, Teodora Serban, Gerolamo Bianchi, Luca Cantarini, Francesco Ciccia, Lorenzo Dagna, Marcello Govoni, Carlomaurizio Montecucco, Roberta Priori, Angelo Ravelli, Paolo Sfriso, Luigi Sinigaglia, AOSD Consensus Group

Published in: Arthritis Research & Therapy | Issue 1/2020

Excerpt

Correction to: Arthritis Res Ther (2019) 21:275 …

Colafrancesco S, et al. Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Res Ther. 2019;21:275. https://doi.org/10.1186/s13075-019-2021-9.CrossRefPubMedPubMedCentral

Title: Correction to: Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
Authors: Serena Colafrancesco
Maria Manara
Alessandra Bortoluzzi
Teodora Serban
Gerolamo Bianchi
Luca Cantarini
Francesco Ciccia
Lorenzo Dagna
Marcello Govoni
Carlomaurizio Montecucco
Roberta Priori
Angelo Ravelli
Paolo Sfriso
Luigi Sinigaglia
AOSD Consensus Group
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2020
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-019-2094-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study

Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase

Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study

Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials